Hologic, Inc. (NASDAQ:HOLX) Shares Sold by ING Groep NV

ING Groep NV reduced its holdings in Hologic, Inc. (NASDAQ:HOLX) by 72.5% in the 4th quarter, Holdings Channel reports. The institutional investor owned 9,093 shares of the medical equipment provider’s stock after selling 24,028 shares during the quarter. ING Groep NV’s holdings in Hologic were worth $656,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of HOLX. General Partner Inc. acquired a new position in Hologic during the fourth quarter worth $26,000. Venturi Wealth Management LLC raised its holdings in Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after purchasing an additional 261 shares during the last quarter. First Horizon Advisors Inc. raised its holdings in Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 134 shares during the last quarter. Covestor Ltd raised its holdings in Hologic by 23.8% during the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock worth $56,000 after purchasing an additional 133 shares during the last quarter. Finally, Loomis Sayles & Co. L P raised its holdings in Hologic by 29.3% during the third quarter. Loomis Sayles & Co. L P now owns 808 shares of the medical equipment provider’s stock worth $66,000 after purchasing an additional 183 shares during the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.88% of the company’s stock.

Hologic Price Performance

Shares of NASDAQ:HOLX opened at $65.01 on Tuesday. The company has a market cap of $14.59 billion, a P/E ratio of 20.51, a P/E/G ratio of 2.14 and a beta of 0.98. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 52 week low of $62.69 and a 52 week high of $84.67. The business has a fifty day simple moving average of $69.76 and a 200-day simple moving average of $76.41.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Equities research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on HOLX. Stephens reaffirmed an “overweight” rating and set a $84.00 price objective on shares of Hologic in a report on Thursday, February 6th. StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. Leerink Partnrs cut Hologic from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th. BNP Paribas raised Hologic to a “strong-buy” rating in a report on Tuesday, December 10th. Finally, Morgan Stanley cut their price target on Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Ten analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $85.77.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.